JP4958785B2 - 複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼインヒビターとしてのそれらの使用 - Google Patents

複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼインヒビターとしてのそれらの使用 Download PDF

Info

Publication number
JP4958785B2
JP4958785B2 JP2007532640A JP2007532640A JP4958785B2 JP 4958785 B2 JP4958785 B2 JP 4958785B2 JP 2007532640 A JP2007532640 A JP 2007532640A JP 2007532640 A JP2007532640 A JP 2007532640A JP 4958785 B2 JP4958785 B2 JP 4958785B2
Authority
JP
Japan
Prior art keywords
alkyl
group
radical
hydrogen
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007532640A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008513504A5 (enExample
JP2008513504A (ja
Inventor
ラジェンダー カンボジ，
ザイホイ チャン，
チーアン−ミン フ，
バンドナ ライナ，
サーグェイ スビリドフ，
ビシュヌマーシー コドゥムル，
ナガスリー チャッカ，
シーフェン リュー，
シャオイー サン，
デュアンチー フー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenon Pharmaceuticals Inc
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of JP2008513504A publication Critical patent/JP2008513504A/ja
Publication of JP2008513504A5 publication Critical patent/JP2008513504A5/ja
Application granted granted Critical
Publication of JP4958785B2 publication Critical patent/JP4958785B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2007532640A 2004-09-20 2005-09-20 複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼインヒビターとしてのそれらの使用 Expired - Fee Related JP4958785B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61164304P 2004-09-20 2004-09-20
US60/611,643 2004-09-20
PCT/US2005/033801 WO2006101521A2 (en) 2004-09-20 2005-09-20 Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors

Publications (3)

Publication Number Publication Date
JP2008513504A JP2008513504A (ja) 2008-05-01
JP2008513504A5 JP2008513504A5 (enExample) 2008-10-16
JP4958785B2 true JP4958785B2 (ja) 2012-06-20

Family

ID=37024256

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007532640A Expired - Fee Related JP4958785B2 (ja) 2004-09-20 2005-09-20 複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼインヒビターとしてのそれらの使用

Country Status (10)

Country Link
US (2) US7592343B2 (enExample)
EP (2) EP1804799B1 (enExample)
JP (1) JP4958785B2 (enExample)
CN (1) CN101083993A (enExample)
AR (1) AR051093A1 (enExample)
AU (1) AU2005329423A1 (enExample)
BR (1) BRPI0515482A (enExample)
CA (1) CA2580857A1 (enExample)
TW (1) TW200626139A (enExample)
WO (1) WO2006101521A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
EP1804799B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
MX2007003321A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
WO2006034312A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coa-desaturase (scd)
MX2007003327A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
TW200626153A (en) * 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
AR051094A1 (es) * 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
CN101083982A (zh) 2004-09-20 2007-12-05 泽农医药公司 用于治疗硬脂酰CoA去饱和酶介导的疾病的杂环衍生物
CN101084207A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
EP1807085B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
WO2008024390A2 (en) 2006-08-24 2008-02-28 Novartis Ag 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyraz0l-3-yl) -thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other disorders
TW200826936A (en) 2006-12-01 2008-07-01 Merck Frosst Canada Ltd Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
GB0625654D0 (en) * 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
GB0625594D0 (en) * 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
GB0625604D0 (en) * 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
GB0625605D0 (en) * 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
AR064965A1 (es) 2007-01-26 2009-05-06 Merck Frosst Canada Inc Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa
US8575167B2 (en) 2007-02-06 2013-11-05 Takeda Pharmaceutical Company Limited Spiro compounds having stearoyl-CoA desaturase action
US20080255161A1 (en) * 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
JP2010524987A (ja) 2007-04-27 2010-07-22 サノフィ−アベンティス ２−ヘテロアリール−ピロロ［３，４−ｃ］ピロール誘導体及びｓｃｄ阻害剤としてのそれらの使用
CN101932570B (zh) * 2007-04-27 2014-11-26 普渡制药公司 Trpv1拮抗剂以及其用途
WO2008157844A1 (en) 2007-06-21 2008-12-24 Forest Laboratories Holdings Limited Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
GB0714129D0 (en) * 2007-07-19 2007-08-29 Smithkline Beecham Corp compounds
GB0715055D0 (en) * 2007-08-02 2007-09-12 Smithkline Beecham Corp Compounds
GB0722075D0 (en) 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
JP2012505881A (ja) * 2008-10-15 2012-03-08 ギリアード サイエンシーズ， インコーポレイテッド ステアロイル−ＣｏＡデサチュラーゼの阻害剤として使用するための３−ヒドロキナゾリン−４−オン誘導体
US9168248B2 (en) 2009-02-17 2015-10-27 Merck Canada Inc. Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
EP2398796A4 (en) * 2009-02-23 2012-10-10 Merck Canada Inc HETEROCYCLIC DERIVATIVES AS INHIBITORS OF THE STEAROYL COENZYME A DELTA 9 DESATURASE
EP2459568A4 (en) 2009-07-28 2013-02-27 Merck Frosst Canada Ltd NEW SPIRO COMPOUNDS AS AN INHIBITORS OF STEAROYL COENZYME A DELTA 9 DESATURASE
WO2011030312A1 (en) 2009-09-10 2011-03-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES
EP3173411B1 (en) 2011-06-22 2018-05-09 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
KR20140084164A (ko) 2011-10-15 2014-07-04 제넨테크, 인크. 암의 치료를 위한 scd1 길항제
WO2013134546A1 (en) 2012-03-07 2013-09-12 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2013175474A2 (en) 2012-05-22 2013-11-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Selective inhibitors of undifferentiated cells
US10301273B2 (en) 2014-08-07 2019-05-28 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
SMT201900517T1 (it) 2017-03-20 2019-11-13 Forma Therapeutics Inc Composizioni di pirrolopirrolo come attivatori di piruvato chinasi (pkr)
ES2968678T3 (es) * 2018-04-27 2024-05-13 Univ Osaka Inhibidores del canal TRPC3 o TRPC6
CN113166060B (zh) 2018-09-19 2024-01-09 诺沃挪第克健康护理股份公司 用丙酮酸激酶激活化合物治疗镰状细胞病
US11001588B2 (en) 2018-09-19 2021-05-11 Forma Therapeutics, Inc. Activating pyruvate kinase R and mutants thereof
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
AU2019387367A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
CA3151612A1 (en) 2019-09-19 2021-03-25 George P. Luke Pyruvate kinase r (pkr) activating compositions
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (303)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2985657A (en) * 1959-10-12 1961-05-23 Paul A J Janssen 1-(aroylalkyl)-4-heterocyclylpiperazines
DE1670684A1 (de) * 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
US3830924A (en) * 1966-12-23 1974-08-20 American Cyanamid Co Substituted nitroimidazolyl-thiadiazoles as growth promoting agents
AT340933B (de) * 1973-08-20 1978-01-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
DE2341925A1 (de) 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
DE2516040C2 (de) * 1974-06-10 1984-12-20 Dr. Karl Thomae Gmbh, 7950 Biberach Benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE2427943C2 (de) 1974-06-10 1984-08-02 Dr. Karl Thomae Gmbh, 7950 Biberach Benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
NL171985C (nl) 1976-02-10 1983-06-16 Rhone Poulenc Ind Werkwijze voor het bereiden van preparaten met werking tegen schistosomiasis, de aldus verkregen gevormde preparaten en werkwijze voor het bereiden van 1,2-dithioolverbindingen.
DE2965377D1 (en) * 1978-10-02 1983-06-16 Lepetit Spa 6-amino substituted n-pyrrolyl-3-pyridazine amines, their preparation, and pharmaceutically antihypertensive compositions containing them
US4247551A (en) * 1979-09-17 1981-01-27 Gruppo Lepetit S.P.A. N-Pyrrolyl-pyridazineamines and their use as antihypertensive agents
FI70411C (fi) * 1980-12-29 1986-09-19 Pfizer Foerfarande foer framstaellning av nya antihypertensiva 4-amino-6,7-dimetoxi-2-piperazinokinazolin derivat
CH653021A5 (fr) * 1981-04-24 1985-12-13 Delalande Sa Derives piperidino, piperazino et homopiperazino, n-substitues par un groupe heterocyclique aromatique, leur procede de preparation et composition therapeutique les contenant.
US4439606A (en) * 1982-05-06 1984-03-27 American Cyanamid Company Antiatherosclerotic 1-piperazinecarbonyl compounds
CH655103A5 (de) 1983-03-11 1986-03-27 Sandoz Ag Azolderivate, verfahren zu ihrer herstellung und ihre verwendung.
PL147465B1 (en) * 1984-03-26 1989-06-30 Janssen Pharmaceutica Nv Method of obtaining novel pyridazionoamine compounds
US5001125A (en) 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
EP0200024B1 (de) 1985-04-30 1992-07-01 ARZNEIMITTELWERK DRESDEN GmbH 3-Cyan-pyridine, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
ES8802151A1 (es) 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
DE3536030A1 (de) 1985-10-09 1987-04-09 Thomae Gmbh Dr K Verwendung von benzimidazolen zur behandlung der migraene
WO1988007527A1 (en) 1987-04-03 1988-10-06 The Upjohn Company Amino-9,10-secosteroids
CA1338012C (en) 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
NZ225045A (en) 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
MY104343A (en) 1987-11-23 1994-03-31 Janssen Pharmaceutica Nv Novel pyridizinamine deravatives
DE3827599A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Verwendung von optisch aktiven tetrahydrofuran-2-carbonsaeureestern als dotierstoffe in fluessigkristallmischungen, diese enthaltende fluessigkristallmischungen und neue optisch aktive tetrahydrofuran-2-carbonsaeureester
US4994456A (en) 1989-03-01 1991-02-19 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
CA2071529C (en) 1989-12-28 2001-03-20 Donna Lee Romero Diaromatic substituted anti-aids compounds
EP0507863A4 (en) 1989-12-28 1993-07-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
IL96891A0 (en) 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
US5166147A (en) * 1990-07-09 1992-11-24 The Du Pont Merck Pharmaceutical Company 4-heteroaryl-and 4-aryl-1,4-dihydropyridine, derivatives with calcium agonist and alpha1 -antagonist activity
EP0471201A1 (de) * 1990-07-21 1992-02-19 Hoechst Aktiengesellschaft Neue Oxazolidinon-Derivate und ihre Verwendung als Dotierstoffe in Flüssigkristallmischungen
DE4031000A1 (de) 1990-10-01 1992-04-09 Hoechst Ag 4- oder 5-substituierte pyridin-2-carbonsaeuren, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
IT1245712B (it) 1991-04-09 1994-10-14 Boehringer Mannheim Italia Ammine eterocicliche utili terapia dell'asma e dell'infiammazione delle vie aeree
EP0520292A1 (de) * 1991-06-19 1992-12-30 Hoechst Aktiengesellschaft Chirale Azetidinon-Derivate und ihre Verwendung als Dotierstoffe in Flüssigkristallmischungen
PT100639A (pt) 1991-06-27 1993-09-30 Univ Virginia Commonwealth Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina
EP0594702B1 (en) 1991-07-03 1997-01-29 PHARMACIA & UPJOHN COMPANY Substituted indoles as anti-aids pharmaceuticals
EP0524146A1 (de) 1991-07-19 1993-01-20 Ciba-Geigy Ag Aminosubstituierte Piperazinderivate
DE4124942A1 (de) * 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9117639D0 (en) 1991-08-15 1991-10-02 Ici Plc Therapeutic compounds
JPH05255089A (ja) 1991-12-18 1993-10-05 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
JPH05345780A (ja) * 1991-12-24 1993-12-27 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
AU3351293A (en) 1992-01-21 1993-08-03 Glaxo Group Limited Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
EP0630370A1 (en) 1992-03-11 1994-12-28 E.I. Du Pont De Nemours And Company Fungicidal oxazolidinones
HU209678B (en) 1992-06-09 1994-10-28 Richter Gedeon Vegyeszet Process for producing biologically active eburnamenin-14-carbonyl-amino derivatives and pharmaceutical compositions containing them
IT1255704B (it) 1992-09-30 1995-11-10 Boehringer Mannheim Italia Ammine eterocicliche utili nella terapia dell'asma e dell'infiammazione delle vie aeree
DE4236106A1 (de) * 1992-10-26 1994-04-28 Hoechst Ag Azaaromatische Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung in flüssigkristallinen Mischungen
US5494908A (en) 1992-11-23 1996-02-27 Hoechst-Roussel Pharmaceutical Incorporated Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds
US5380726A (en) * 1993-01-15 1995-01-10 Ciba-Geigy Corporation Substituted dialkylthio ethers
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
JP3377826B2 (ja) 1993-05-06 2003-02-17 ヘキスト・アクチェンゲゼルシャフト 液晶組成物に使用するための新規化合物
US5547605A (en) * 1993-12-15 1996-08-20 Hoechst Aktiengesellschaft 2-Aryloxytetrafluoropropionic esters, process for their preparation, and their use in liquid-crystalline mixtures
DE4343286A1 (de) 1993-12-17 1995-06-22 Hoechst Ag Heteroaromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen
DE19502178A1 (de) * 1994-01-27 1995-08-03 Hoechst Ag Thiadiazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Vorprodukte zur Herstellung von Flüssigkristallen
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
DE4423044A1 (de) 1994-07-01 1996-01-04 Hoechst Ag 1-(3-Alkyloxiran-2-yl)alkylester mesogener Carbonsäuren und ihre Verwendung in flüssigkristallinen Mischungen
US5571811A (en) * 1994-07-12 1996-11-05 Janssen Pharmaceutica N.V. Sulfonamide derivatives of azolones
US5607932A (en) 1994-07-12 1997-03-04 Janssen Pharmaceutica N.V. Heterocyclic derivatives of azolones
US5637592A (en) * 1994-07-12 1997-06-10 Janssen Pharmaceutica N.V. Acyl derivatives of azolones
RU2165423C2 (ru) 1994-10-07 2001-04-20 Фудзисава Фармасьютикал Ко., Лтд. Полипептидное соединение, способ его получения и фармацевтическая композиция
US5702637A (en) 1995-04-19 1997-12-30 Minnesota Mining And Manufacturing Company Liquid crystal compounds having a chiral fluorinated terminal portion
US5668148A (en) * 1995-04-20 1997-09-16 Merck & Co., Inc. Alpha1a adrenergic receptor antagonists
DE19517060A1 (de) 1995-05-10 1996-11-14 Hoechst Ag 1-Fluorisochinolinderivate und ihre Verwendung in flüssigkristallinen Mischungen
DE19517038A1 (de) * 1995-05-10 1996-11-14 Hoechst Ag 1,8-Difluorisochinolinderivate und ihre Verwendung in flüssigkristallinen Mischungen
DE19517051A1 (de) * 1995-05-10 1996-11-14 Hoechst Ag 1-Fluor-6,7-dihydro-5H-isochinolin-8-on-Derivate und ihre Verwendung in flüssigkristallinen Mischungen
DE19517056A1 (de) * 1995-05-10 1996-11-14 Hoechst Ag 1-Fluor-5,6,7,8-tetrahydroisochinolin-Derivate und ihre Verwendung in flüssigkristallinen Mischungen
DE19517025A1 (de) 1995-05-10 1996-11-14 Hoechst Ag Trifluortetrahydroisochinolin-Derivate und ihre Verwendung in flüssigkristallinen Mischungen
TW357143B (en) 1995-07-07 1999-05-01 Novartis Ag Benzo[g]quinoline derivatives
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
ZA969622B (en) 1995-12-13 1998-05-15 Upjohn Co Oxazolidinone antibacterial agents having a six-membered heteroaromatic ring.
CN1104430C (zh) 1996-01-15 2003-04-02 詹森药业有限公司 抑制血管生成的哒嗪胺
US6313127B1 (en) 1996-02-02 2001-11-06 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
DE19614204A1 (de) 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JPH107572A (ja) 1996-06-17 1998-01-13 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生阻害剤
GB9614238D0 (en) * 1996-07-06 1996-09-04 Zeneca Ltd Chemical compounds
DE19630068A1 (de) 1996-07-25 1998-01-29 Basf Ag Neue flüssigkristalline Verbindungen und deren Vorprodukte
EP0929553B1 (en) 1996-10-02 2005-03-16 Novartis AG Pyrimidine derivatives and processes for the preparation thereof
DE59707681D1 (de) * 1996-10-28 2002-08-14 Rolic Ag Zug Vernetzbare, photoaktive Silanderivate
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
AU8096798A (en) 1997-06-27 1999-01-19 Resolution Pharmaceuticals Inc. Dopamine d4 receptor ligands
CN1239570A (zh) 1997-07-17 1999-12-22 索尼公司 磁记录介质和使用该介质的磁记录/再现装置
ES2125206B1 (es) * 1997-07-21 1999-11-16 Esteve Labor Dr Derivados de acil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos.
SE9703377D0 (sv) 1997-09-18 1997-09-18 Astra Ab New compounds
AR013693A1 (es) 1997-10-23 2001-01-10 Uriach & Cia Sa J Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
CZ299499B6 (cs) 1997-10-27 2008-08-13 Neurosearch A/S Homopiperazinový derivát, farmaceutická kompoziceho obsahující a jeho použití
WO1999033805A1 (en) 1997-12-26 1999-07-08 Mochida Pharmaceutical Co., Ltd. Aromatic compounds having cyclic amino or salts thereof
DK1054874T3 (da) 1998-02-13 2002-12-30 Upjohn Co Substituerede aminophenylisoxazolinderivater, der er anvendelige som antimokrobielle midler
EP1060179A1 (en) 1998-02-25 2000-12-20 PHARMACIA & UPJOHN COMPANY Substituted aminomethyl isoxazoline derivatives useful as antimicrobials
DK1064273T3 (da) 1998-03-19 2003-03-31 Upjohn Co 1,3,4-Thiadiazoler, som er nyttige til behandling af CMV-infektioner
DE59914996D1 (en) 1998-04-20 2009-05-14 Abbott Gmbh & Co Kg Heterocyclisch substituierte amide als calpainhemmer
WO1999055675A1 (de) 1998-04-29 1999-11-04 Axiva Gmbh Verfahren zur katalytischen herstellung von substituierten bipyridylderivaten
KR100579792B1 (ko) 1998-05-13 2006-05-12 동화약품공업주식회사 신규 2,5-피리딘디카복실산 유도체
NZ508174A (en) 1998-06-05 2003-10-31 Astrazeneca Ab Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
GB9812019D0 (en) 1998-06-05 1998-07-29 Zeneca Ltd Chemical compounds
ATE273298T1 (de) * 1998-08-25 2004-08-15 Ortho Mcneil Pharm Inc Pyridyl-ether und -thioether als nikotin- acetylcholin-rezeptorliganden und ihre therapeutische anwendung
ATE259803T1 (de) 1998-10-09 2004-03-15 Janssen Pharmaceutica Nv 4,5-dehydroisoxazole derivate und ihre pharmazeutische verwendung
DE69913558T2 (de) * 1998-10-21 2004-11-04 Takeda Chemical Industries, Ltd. Kondensierte pyridazinderivate, verfahren zu ihrer herstellung und ihre anwendung
AU1455500A (en) 1998-10-29 2000-05-22 Trega Biosciences, Inc. Oxadiazole, thiadiazole and triazole derivatives and combinatorial libraries thereof
AU1549500A (en) 1998-12-02 2000-06-19 Novo Nordisk A/S Use of n-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis
GB9826412D0 (en) 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
EP1156045A4 (en) 1999-01-28 2002-04-17 Nippon Shinyaku Co Ltd AMID DERIVATIVES AND DRUG COMPOSITIONS
EP1359152B1 (en) 1999-01-29 2008-05-07 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
AU4166400A (en) 1999-02-11 2000-08-29 Cor Therapeutics, Inc. Alkenyl and alkynyl compounds as inhibitors of factor xa
ES2226622T3 (es) 1999-02-24 2005-04-01 F. Hoffmann-La Roche Ag Derivados de 4-fenil piridina y su empleo como antagonistas del receptor nk-1.
HUP0202248A3 (en) 1999-03-12 2006-06-28 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
PT1165085E (pt) 1999-03-30 2006-10-31 Novartis Ag Derivados de ftalazina para tratar doencas inflamatorias
WO2000061556A1 (en) 1999-04-09 2000-10-19 Meiji Seika Kaisha, Ltd. Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same
FR2792314B1 (fr) * 1999-04-15 2001-06-01 Adir Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2935200A (en) 1999-04-30 2000-11-17 Pfizer Products Inc. Compounds for the treatment of obesity
DE19922723A1 (de) 1999-05-18 2000-11-23 Clariant Gmbh Aktivmatrix-Displays mit hohem Kontrast
WO2000071536A1 (en) 1999-05-20 2000-11-30 E.I. Du Pont De Nemours And Company Heteroaryloxypyrimidine insecticides and acaricides
GB9912413D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
WO2001007409A1 (en) 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
DE19934799B4 (de) * 1999-07-28 2008-01-24 Az Electronic Materials (Germany) Gmbh Chiral-smektische Flüssigkristallmischung und ihre Verwendung in Aktivmatrix-Displays mit hohen Kontrastwerten
US6127382A (en) * 1999-08-16 2000-10-03 Allergan Sales, Inc. Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
DE60039359D1 (de) 1999-09-04 2008-08-14 Astrazeneca Ab Amide als pyruvatdehydrogenaseinhibitoren
US6156758A (en) 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
AUPQ288499A0 (en) * 1999-09-16 1999-10-07 Biota Scientific Management Pty Ltd Antiviral agents
MX228790B (es) 1999-09-17 2005-06-30 Millennium Pharm Inc Inhibidores del factor xa.
SK285240B6 (sk) 1999-09-24 2006-09-07 Janssen Pharmaceutica N. V. Antivírusové prostriedky
US6677452B1 (en) * 1999-09-30 2004-01-13 Lion Bioscience Ag Pyridine carboxamide or sulfonamide derivatives and combinatorial libraries thereof
WO2001032628A1 (en) 1999-11-03 2001-05-10 Bristol-Myers Squibb Pharma Company Cyano compounds as factor xa inhibitors
WO2001043746A1 (en) 1999-12-14 2001-06-21 Nippon Shinyaku Co., Ltd. Medicinal composition
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
US6518285B2 (en) 1999-12-21 2003-02-11 Ortho Mcneil Pharmaceutical, Inc. Piperidinyloxy and pyrrolidinyloxy oxazolidinone antibacterials
JP2003519143A (ja) 1999-12-28 2003-06-17 ファーマコピーア，インコーポレーティッド ピリミジン及びトリアジン系キナーゼ阻害剤
AU2001238424A1 (en) 2000-02-18 2001-08-27 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
AU2001243158A1 (en) 2000-02-18 2001-08-27 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
ATE475718T1 (de) * 2000-02-24 2010-08-15 Xenon Pharmaceuticals Inc Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika
HUP0300029A2 (en) 2000-02-25 2003-05-28 Hoffmann La Roche Adenosine receptor modulators, pharmaceutical compositions containing them and their use
US6605615B2 (en) 2000-03-01 2003-08-12 Tularik Inc. Hydrazones and analogs as cholesterol lowering agents
EP1339702A1 (en) 2000-03-15 2003-09-03 Warner-Lambert Company 5-amide substituted diarylamines as mek inhibitors
WO2001068619A1 (en) 2000-03-15 2001-09-20 Warner-Lambert Company 5-amide substituted diarylamines as mex inhibitors
US6613917B1 (en) 2000-03-23 2003-09-02 Allergan, Inc. Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US20020045613A1 (en) * 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
CZ20023562A3 (cs) 2000-04-28 2003-03-12 Sankyo Company, Limited PPAR gama modulátory
AU4114201A (en) 2000-04-28 2001-11-12 Tanabe Seiyaku Co Cyclic compounds
GB0010757D0 (en) * 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
GB0013378D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
GB0013383D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0030304D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
WO2002008221A2 (en) 2000-07-20 2002-01-31 Neurogen Corporation Capsaicin receptor ligands
EP1307444B1 (en) * 2000-07-27 2007-10-03 Eli Lilly And Company Substituted heterocyclic amides
HRP20030081A2 (en) * 2000-08-08 2005-02-28 Sanofi-Aventis Benzimidazole derivatives, preparation and therapeutic use thereof
EP1184442A1 (en) 2000-08-30 2002-03-06 Clariant International Ltd. Liquid crystal mixture
CA2430987A1 (en) 2000-09-26 2002-04-04 Xenon Genetics, Inc. Methods and compositions employing a novel stearoyl-coa desaturase-hscd5
FR2815032B1 (fr) * 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
MXPA03003264A (es) 2000-10-13 2003-06-06 Neurosearch As Tratamiento de trastornos afectivos mediante la accion combinada de un agonista del receptor nicotinico y una sustancia monoaminergica.
JP4170753B2 (ja) 2000-10-17 2008-10-22 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー オキサゾリジノン化合物の製造方法
DE10060412A1 (de) 2000-12-05 2002-06-06 Bayer Ag DELTA1-Pyrroline
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
WO2002055496A1 (en) 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
US7026314B2 (en) 2001-01-16 2006-04-11 Astrazeneca Ab Therapeutic chromone compounds
JP4280068B2 (ja) 2001-01-16 2009-06-17 アストラゼネカ・アクチエボラーグ 治療用クロマン化合物
EP1353913A2 (en) 2001-01-16 2003-10-22 AstraZeneca AB Therapeutic heterocyclic compounds
ES2317116T3 (es) 2001-02-16 2009-04-16 Aventis Pharmaceuticals Inc. Derivados de carbonilos sustituidos heterociclicos y su uso como ligandos del receptor de dopamina d3.
US7126003B2 (en) 2001-03-07 2006-10-24 Daiichi Pharmaceutical Co., Ltd. Method for producing 2-azetidinone derivative
US20020169166A1 (en) 2001-03-09 2002-11-14 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
EP1373204B1 (en) 2001-03-09 2016-10-26 Janssen Pharmaceuticals, Inc. Heterocyclic compounds
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
CN1509275A (zh) * 2001-03-15 2004-06-30 金属蛋白酶抑制剂
DK1373218T3 (da) 2001-03-29 2008-05-19 Ortho Mcneil Pharm Inc Imidazolylderivater til anvendelse som histamin H3-receptorligander
FR2823209B1 (fr) * 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
CZ20032831A3 (cs) 2001-04-16 2004-03-17 Schering Corporation 3,4-Disubstituované cyklobuten-1,2-diony
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US6911447B2 (en) * 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
US20050009834A1 (en) 2001-05-09 2005-01-13 Shigeyuki Itoh Azole compounds, process for preparation of the same and use thereof
US20030187007A1 (en) 2001-05-30 2003-10-02 Cao Sheldon Xiaodong Inhibitors of protein kinase for the treatment of disease
PL367205A1 (en) * 2001-06-15 2005-02-21 Yamanouchi Pharmaceutical Co, Ltd. Phenylpyridine carbonyl piperazine derivative
WO2003003008A1 (en) 2001-06-29 2003-01-09 7Tm Pharma A/S Chemical libraries useful for drug discovery processes
WO2003004488A1 (en) * 2001-07-03 2003-01-16 Chiron Corporation Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
US7115607B2 (en) * 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
MXPA04000906A (es) 2001-08-03 2004-11-22 Novo Nordisk As Nuevos derivados de 2,4-diaminotiazol.
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
WO2003018563A1 (en) 2001-08-31 2003-03-06 Northwestern University Anti-inflammatory and protein kinase inhibitor composition and method of use
JP2005504789A (ja) 2001-09-13 2005-02-17 シンタ ファーマスーティカルズ コーポレイション 癌治療のための２−アロイルイミダゾール化合物
FR2829926B1 (fr) * 2001-09-26 2004-10-01 Oreal Composition pour la teinture des fibres keratiniques comprenant un colorant diazoique dicationique particulier
US6916812B2 (en) * 2001-10-09 2005-07-12 Bristol-Myers Squibb Company Alpha-aminoamide derivatives as melanocortin agonists
US6824707B2 (en) * 2001-10-23 2004-11-30 Clariant International Ltd. Active matrix liquid crystal device and smectic liquid crystal mixture
WO2003035602A1 (en) 2001-10-25 2003-05-01 Sankyo Company, Limited Lipid modulators
WO2003037862A1 (en) 2001-10-30 2003-05-08 Nippon Shinyaku Co., Ltd. Amide derivatives and drugs
SE0103649D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
SE0103648D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
GB0127008D0 (en) 2001-11-09 2002-01-02 Novartis Ag Organic compounds
US6620811B2 (en) 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
CA2468159A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 4-aminoquinoline compounds
JP2005510564A (ja) 2001-11-28 2005-04-21 藤沢薬品工業株式会社 アポリポタンパク質ｂ阻害剤としての複素環式アミド化合物
US7163952B2 (en) 2001-12-03 2007-01-16 Japan Tobacco Inc. Azole compound and medicinal use thereof
FR2833261B1 (fr) 2001-12-06 2004-07-02 Yang Ji Chemical Company Ltd Nouveaux composes inhibiteurs specifiques de la phospholipase a2 secretee non pancreatique humaine du groupe ii
AU2002350172A1 (en) 2001-12-07 2003-06-23 Eli Lilly And Company Substituted heterocyclic carboxamides with antithrombotic activity
US6806279B2 (en) 2001-12-17 2004-10-19 Sunesis Pharmaceuticals, Inc. Small-molecule inhibitors of interleukin-2
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
US7390813B1 (en) * 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
US20030166932A1 (en) * 2002-01-04 2003-09-04 Beard Richard L. Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
IL162859A0 (en) * 2002-02-05 2005-11-20 Novo Nordisk As Novel aryl-and heteroarylpiperazines
CA2476586C (en) 2002-03-13 2011-11-01 Janssen Pharmaceutica N.V. Sulfonyl-derivatives as novel inhibitors of histone deacetylase
EP1485354B1 (en) 2002-03-13 2008-05-28 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
JP4725944B2 (ja) 2002-03-13 2011-07-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの阻害剤
BR0307607A (pt) 2002-03-13 2004-12-21 Janssen Pharmaceutica Nv Derivados de carbonilamino como inibidores de histona desacetilase
AR038966A1 (es) 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
WO2003080060A1 (en) 2002-03-20 2003-10-02 Schering Aktiengesellschaft Substituted piperazine antithrombotic pai-1 inhibitors
DE10217006A1 (de) 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
WO2003091247A2 (en) 2002-04-25 2003-11-06 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
US6982259B2 (en) 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
JP2005289816A (ja) 2002-05-14 2005-10-20 Banyu Pharmaceut Co Ltd ベンズイミダゾール誘導体
HUP0202001A2 (hu) 2002-06-14 2005-08-29 Sanofi-Aventis DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok
WO2004000318A2 (en) 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
US20040082627A1 (en) 2002-06-21 2004-04-29 Darrow James W. Certain aromatic monocycles as kinase modulators
WO2004009587A1 (en) 2002-07-22 2004-01-29 Orchid Chemicals & Pharmaceuticals Ltd Oxazolidinone derivatives as antibacterial agents
WO2004011430A1 (ja) 2002-07-25 2004-02-05 Yamanouchi Pharmaceutical Co., Ltd. ナトリウムチャネル阻害剤
WO2004010927A2 (en) 2002-07-25 2004-02-05 Wisconsin Alumni Research Foundation Method for increasing insulin sensitivity and for treating and preventing type 2 diabetes
AU2003264047B2 (en) 2002-08-08 2008-06-26 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP2006501260A (ja) 2002-09-04 2006-01-12 シェーリング　コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
KR20050057226A (ko) 2002-09-06 2005-06-16 얀센 파마슈티카 엔.브이. 알레르기성 비염 치료용 약제를 제조하기 위한 인돌릴 유도체의 용도
AU2003256003A1 (en) 2002-09-18 2004-04-08 Pfizer Products Inc. Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors
JP2006506443A (ja) 2002-09-18 2006-02-23 ファイザー・プロダクツ・インク 形質転換成長因子（ｔｇｆ）阻害剤としての新規なイソチアゾール及びイソキサゾール化合物
US7582761B2 (en) 2002-10-17 2009-09-01 Amgen Inc. Vanilloid receptor ligands and their use in treatments
GB0224919D0 (en) 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy
DE10250708A1 (de) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US20040097492A1 (en) * 2002-11-01 2004-05-20 Pratt John K Anti-infective agents
FR2847253B1 (fr) 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
DE10254875A1 (de) 2002-11-25 2004-06-03 Bayer Healthcare Ag Phenylsulfoxid und -sulfon-Derivate
JP2004203871A (ja) 2002-12-13 2004-07-22 Yamanouchi Pharmaceut Co Ltd 医薬組成物
DE10259382A1 (de) * 2002-12-18 2004-07-01 Abbott Gmbh & Co. Kg 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-4-on-Derivate, ihre Herstellung und Verwendung
AU2003299791A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
EP1590341B1 (en) 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
US20050130989A1 (en) * 2003-01-28 2005-06-16 Aventis Pharma S. A. N-arylheteroaromatic products compositions containing them and use thereof
ATE551324T1 (de) 2003-02-03 2012-04-15 Janssen Pharmaceutica Nv Chinolin-amid-derivate als modulatoren von vanilloid-vr1-rezeptoren
GB0302671D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
DE602004015254D1 (de) 2003-02-07 2008-09-04 Janssen Pharmaceutica Nv Hiv-inhibierende1,2,4-triazine
HRP20050688B1 (hr) 2003-02-07 2017-03-24 Janssen Pharmaceutica N.V. Derivati pirimidina za sprječavanje hiv infekcije
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
CN1753873A (zh) 2003-02-22 2006-03-29 默克专利股份有限公司 作为液晶的氰基吡啶酮衍生物
DK1606282T3 (da) 2003-02-24 2009-03-16 Arena Pharm Inc Phenyl- og pyridylpipereidinye-derivater som modulatorer af glucosemetabolisme
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
WO2004078716A1 (en) 2003-03-03 2004-09-16 Merck & Co. Inc. Acylated piperazine derivatives as melanocortin-4 receptor agonists
JP2006522750A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法
CA2523831C (en) 2003-04-29 2008-11-18 Pfizer Inc. 5,7-diaminopyrazolo[4,3-d]pyrimidines useful in the treatment of hypertension
WO2004110350A2 (en) 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
DE10322408A1 (de) 2003-05-16 2004-12-02 Degussa Ag Stickstoffhaltige monodentate Phosphine und deren Verwendung in der Katalyse
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
PE20050226A1 (es) * 2003-06-04 2005-05-18 Aventis Pharma Sa Productos aril-heteroaromaticos y composiciones que los contienen
US7610411B2 (en) 2003-06-23 2009-10-27 Sharp Kabushiki Kaisha Information processing device, line concentrator, network information processing system having the line concentrator, information processing program and storage medium
US7595316B2 (en) * 2003-06-27 2009-09-29 Banyu Pharmaceutical Co., Ltd. Heteroaryloxy nitrogenous saturated heterocyclic derivative
WO2005003087A2 (en) 2003-07-01 2005-01-13 Orchid Chemicals And Pharmaceuticals Ltd. Oxazole derivatives as antibacterial agents
KR20060120393A (ko) 2003-07-16 2006-11-27 얀센 파마슈티카 엔.브이. 글리코겐 신타아제 키나제 3 저해제로서의트리아졸로피리미딘 유도체
CN100549014C (zh) 2003-07-16 2009-10-14 詹森药业有限公司 作为糖原合酶激酶3抑制剂的三唑并嘧啶衍生物
CA2533397A1 (en) 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
FR2857966A1 (fr) * 2003-07-24 2005-01-28 Aventis Pharma Sa Produits aryl-heteroaromatiques, compositions les contenant et utilisation
CA2533898A1 (en) 2003-07-29 2005-02-10 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
ES2342605T3 (es) * 2003-07-29 2010-07-09 High Point Pharmaceuticals, Llc Piridazinil-piperazinas y su uso como ligandos del receptor histaminico h3.
TW200523262A (en) 2003-07-29 2005-07-16 Smithkline Beecham Corp Inhibitors of AKT activity
HRP20110974T1 (hr) * 2003-07-30 2012-01-31 Xenon Pharmaceuticals Inc. Derivati piperazina i njihova uporaba kao terapeutskih sredstava
WO2005011653A2 (en) 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7754711B2 (en) * 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
EP2316825A1 (en) 2003-07-30 2011-05-04 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
US7456180B2 (en) 2003-07-30 2008-11-25 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
CN1867554B (zh) * 2003-08-11 2011-07-06 弗·哈夫曼-拉罗切有限公司 具有邻-取代的苯基的哌嗪及其作为glyt1抑制剂的用途
EP1657240A4 (en) 2003-08-18 2009-04-08 Fujifilm Finechemicals Co Ltd PYRIDYLTETRAHYDROPYRIDINE, PYRIDYLPIPERIDINE AND METHOD FOR THE PRODUCTION THEREOF
CN101851238B (zh) 2003-08-25 2012-07-18 卓维斯医药品有限责任公司 取代的8-杂芳基黄嘌呤
EP1659123A1 (en) * 2003-08-29 2006-05-24 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic pyrazole derivative
WO2005023260A1 (en) 2003-09-09 2005-03-17 F. Hoffmann-La Roche Ag 1- (2-amino-benzol) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
RU2355683C2 (ru) * 2003-09-09 2009-05-20 Ф.Хоффманн-Ля Рош Аг Производные 1-бензоилпиперазина в качестве ингибиторов поглощения глицина для лечения психозов
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
CA2535313C (en) 2003-09-25 2012-07-17 Janssen Pharmaceutica N.V. Hiv replication inhibiting purine derivatives
AR047759A1 (es) 2003-09-26 2006-02-22 Vertex Pharma Derivados de fenil - piperazina como moduladores de receptores muscarnicos
PL2392565T3 (pl) 2003-09-26 2014-08-29 Exelixis Inc Modulatory c-Met i sposoby stosowania
US7199149B2 (en) 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
WO2005034952A2 (en) 2003-10-07 2005-04-21 The Feinstein Institute For Medical Research Isoxazole and isothiazole compounds useful in the treatment of inflammation
FR2860793A1 (fr) 2003-10-14 2005-04-15 Entomed Composes derives de norcantharidine, leurs procedes de preparation, les compositions les contenant et leurs utilisations
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
WO2005040109A1 (en) 2003-10-22 2005-05-06 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
AU2004283056A1 (en) 2003-10-24 2005-05-06 Solvay Pharmaceuticals Gmbh Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
US20050124660A1 (en) * 2003-10-27 2005-06-09 Jochen Antel Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
US7683059B2 (en) 2003-10-28 2010-03-23 Amgen Inc. Triazole compounds and uses related thereto
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
GB0327323D0 (en) 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
KR20080052683A (ko) 2003-12-18 2008-06-11 인사이트 코포레이션 케모킨 수용체의 조절제로서의3-사이클로알킬아미노피롤리딘 유도체
CA2551038C (en) 2003-12-22 2010-04-27 Pfizer Inc. Triazole derivatives as vasopressin antagonists
US7345043B2 (en) * 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
FR2868780B1 (fr) * 2004-04-13 2008-10-17 Sanofi Synthelabo Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique
JP2008503469A (ja) 2004-06-17 2008-02-07 ワイス ゴナドトロピン放出ホルモン受容体アンタゴニスト
ATE537830T1 (de) 2004-07-06 2012-01-15 Xenon Pharmaceuticals Inc Nicotinamid derivate und ihre verwendung als therapeutika
JP5063351B2 (ja) 2004-09-17 2012-10-31 エグゼリクシス， インコーポレイテッド ピラゾールキナーゼモジュレーターおよび使用方法
CN101084207A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
EP1804799B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
WO2006034312A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coa-desaturase (scd)
MX2007003321A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
EP1807085B1 (en) * 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
TW200626153A (en) * 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
MX2007003327A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
CN101083982A (zh) 2004-09-20 2007-12-05 泽农医药公司 用于治疗硬脂酰CoA去饱和酶介导的疾病的杂环衍生物
AR051094A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
ATE472327T1 (de) 2005-01-07 2010-07-15 Hoffmann La Roche Ä4-(heteroaryl)piperazin-1-ylü-(2,5-substituier e phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
BRPI0611187A2 (pt) * 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
WO2006130986A1 (en) 2005-06-09 2006-12-14 Merck Frosst Canada Ltd. Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
JP2010523653A (ja) * 2007-04-09 2010-07-15 ギリアード・パロ・アルト・インコーポレイテッド ステアロイルＣｏＡデサチュラーゼのインヒビターとして使用するためのプテリジノン誘導体
UA100192C2 (en) * 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands

Also Published As

Publication number Publication date
EP1804799B1 (en) 2013-08-21
AU2005329423A1 (en) 2006-09-28
EP1804799A2 (en) 2007-07-11
US20080125434A1 (en) 2008-05-29
AR051093A1 (es) 2006-12-20
CA2580857A1 (en) 2006-09-28
US8026360B2 (en) 2011-09-27
CN101083993A (zh) 2007-12-05
EP2269610A3 (en) 2011-03-09
BRPI0515482A (pt) 2008-07-22
JP2008513504A (ja) 2008-05-01
EP2269610A2 (en) 2011-01-05
US7592343B2 (en) 2009-09-22
US20090306090A1 (en) 2009-12-10
TW200626139A (en) 2006-08-01
WO2006101521A3 (en) 2006-12-28
WO2006101521A2 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
JP4958785B2 (ja) 複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼインヒビターとしてのそれらの使用
JP5149009B2 (ja) ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体
JP4958787B2 (ja) ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリジン誘導体
JP5080256B2 (ja) 二環式複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼ（ＳＣＤ）のインヒビターとしてのそれらの使用
JP5043668B2 (ja) 複素環誘導体および治療薬としてのそれらの使用
JP5094398B2 (ja) 複素環式誘導体およびステアロイル−ＣｏＡデサチュラーゼのメディエータとしてのそれらの使用
JP4958784B2 (ja) ステアロイル−ＣｏＡデサチュラーゼ酵素によって媒介される疾患の処置のための複素環誘導体
JP4884219B2 (ja) ピリジル誘導体および治療剤としてのその用途
JP4831577B2 (ja) ピリダジン誘導体および治療剤としての用途
JP4838128B2 (ja) ピペラジン誘導体および治療剤としてのその用途
JP4958786B2 (ja) 複素環誘導体および治療薬としてのそれらの使用
JP2008513515A (ja) 複素環誘導体および治療薬としてのそれらの使用
JP2008513505A5 (enExample)
JP2007500719A (ja) ピリジル誘導体および治療剤としてのその用途
MX2007003323A (en) Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111026

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120125

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120302

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120319

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150330

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees